Supriya Lifescience Limited has provided a clarification to the National Stock Exchange of India Limited regarding its financial results submission. The company addressed two queries: the absence of segment details and a delay in submitting the results after the Board Meeting held on November 12, 2025. Regarding the segment details, Supriya Lifescience stated that it operates in a single business segment, Pharmaceuticals. The omission of segment information in the previous submission was attributed to a typographical error that occurred inadvertently. Concerning the delay in submitting the results, the company explained that it encountered technical difficulties with its internal systems during the submission time on November 12, 2025. Despite multiple upload attempts, the issue was resolved, and the filing was completed immediately thereafter. The company has reviewed its internal processes and implemented additional checks to prevent future delays and expressed sincere regret for the error. Supriya Lifescience reaffirmed its commitment to timely and accurate disclosures in compliance with SEBI (LODR) Regulations, 2015.
